卵巢癌诊断中的微流控平台。
Microfluidic platforms in diagnostic of ovarian cancer.
发表日期：2023 Sep 06
作者：
Farnaz Dabbagh Moghaddam, Delara Dadgar, Yasaman Esmaeili, Shahrzad Babolmorad, Ehsan Ilkhani, Maedeh Rafiee, Xiang-Dong Wang, Pooyan Makvandi
来源：
BIOSENSORS & BIOELECTRONICS
摘要：
卵巢癌死亡的最重要原因是该疾病的晚期诊断。卵巢癌的标准治疗包括基于铂的手术和化疗，其副作用对身体有影响。由于临床症状的非特异性特点，需要开发一个早期检测该疾病的平台。近几十年来，微流控设备和系统的进展为卵巢癌的诊断提供了几个优势。利用专业技术设计和制造新平台可能是改善该类疾病的预防、诊断和治疗的重要一步。微流控器官仿生芯片越来越多地被用作癌症研究中有希望的平台，重点关注疾病的特定生物学方面。本综述主要关注卵巢癌和微流控应用技术在其诊断中的应用，并讨论微流控平台及其在促进卵巢癌诊断方面的潜在未来前景。版权所有 © 2023. Elsevier Inc. 发布
The most important reason for death from ovarian cancer is the late diagnosis of this disease. The standard treatment of ovarian cancer includes surgery and chemotherapy based on platinum, which is associated with side effects for the body. Due to the nonspecific nature of clinical symptoms, developing a platform for early detection of this disease is needed. In recent decades, the advancements of microfluidic devices and systems have provided several advantages for diagnosing ovarian cancer. Designing and manufacturing new platforms using specialized technologies can be a big step toward improving the prevention, diagnosis, and treatment of this group of diseases. Organ-on-a-chip microfluidic devices are increasingly used as a promising platform in cancer research, with a focus on specific biological aspects of the disease. This review focusing on ovarian cancer and microfluidic application technologies in its diagnosis. Additionally, it discusses microfluidic platforms and their potential future perspectives in advancing ovarian cancer diagnosis.Copyright © 2023. Published by Elsevier Inc.